Please check your internet connection and try again.
# Clobazam (oral)
## Overview
Clobazam is a benzodiazepine derivative used as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. It has a longer half-life compared to other benzodiazepines.
## Primary Indications
* Adjunctive treatment of seizures in Lennox-Gastaut syndrome (LGS) in patients $\ge$ 2 years of age.
## Adult Dosing
* **Initiation:** 5 mg orally twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on response and tolerability.
* **Maintenance:** Usual dose is 10 mg to 20 mg twice daily.
* **Maximum:** Generally, 20 mg twice daily (40 mg/day). Higher doses (up to 30 mg twice daily or 60 mg/day) have been used in clinical trials for LGS, but caution is advised due to increased risk of adverse effects.
## Pediatric Dosing (Patients $\ge$ 2 years of age)
* **Initiation:** 2.5 mg orally twice daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week based on response and tolerability.
* **Maintenance:** Usual dose is 5 mg to 10 mg twice daily.
* **Maximum:** Generally, 10 mg twice daily (20 mg/day). Higher doses (up to 0.5 mg/kg/day to 1 mg/kg/day divided twice daily, not to exceed 20 mg/day) have been used in clinical trials for LGS.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosage adjustments provided, but consider starting at the lower end of the dosing range and titrating slowly.
* **Renal Impairment:** No specific dosage adjustments provided. Monitor closely for adverse effects.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, drowsiness, lethargy, drooling, constipation, fatigue, aggression, irritability, pyrexia, respiratory tract infections.
* **Serious:** Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior and ideation, respiratory depression, dependence and withdrawal symptoms, cognitive impairment, paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants (alcohol, opioids, other sedatives):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease clobazam concentrations.
* **Phenobarbital, Phenytoin, Primidone:** Clobazam may increase serum concentrations of these antiepileptic drugs. Monitor for toxicity.
* **Central Nervous System (CNS) Stimulants:** May reduce the effectiveness of stimulants.
## Monitoring
* Monitor for seizure frequency and characteristics.
* Assess for adverse effects, particularly somnolence, behavioral changes, and signs of respiratory depression.
* Monitor for signs of withdrawal if discontinued abruptly, especially after prolonged use.
* Monitor serum concentrations of other antiepileptic drugs (phenobarbital, phenytoin, primidone) if coadministered.
* Monitor for suicidal behavior and ideation.
## Clinical Pearls
* Clobazam is intended for adjunctive therapy only.
* Dosing should be individualized based on clinical response and tolerability.
* Taper the dose gradually when discontinuing to avoid withdrawal symptoms.
* Be aware of the potential for severe skin reactions.
* Patients and caregivers should be educated about the risks of somnolence and instructed to avoid operating heavy machinery or driving until they know how the medication affects them.
***
*Disclaimer: This information is intended for clinical use and does not replace a thorough review of the current prescribing information or institutional protocols. Always verify current drug information with the official product labeling and consult with a qualified healthcare professional.*
